Palisade Capital Management
CLVS

Palisade Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Palisade Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16,000
Closed -$102K – 418
2020
Q1 		$102K Buy
16,000
+2,000
+14% +$16K ﹤0.01% 413
2019
Q4 		$146K Sell
14,000
-4,100
-23% -$29.8K ﹤0.01% 407
2019
Q3 		$71K Buy
+18,100
New +$146K ﹤0.01% 420
2015
Q4 		– Sell
-70,937
Closed -$6.52M – 544
2015
Q3 		$6.52M Buy
70,937
+65,437
+1,190% +$5.66M 0.19% 189
2015
Q2 		$483K Buy
+5,500
New +$471K 0.01% 475

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Palisade Capital Management's CLVS Position: Q2 2020 in Review

Palisade Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 16,000 shares — an estimated $102K sold.

Palisade Capital Management first reported a position in CLVS in Q2 2015 and held it in 5 quarters. The position peaked at $6.52M in Q3 2015. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

  • Palisade Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
  • Palisade Capital Management sold 16,000 Clovis Oncology, Inc. shares in Q2 2020, an estimated $102K.
  • Palisade Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 5 quarters.
  • Palisade Capital Management's Clovis Oncology, Inc. position peaked at $6.52M in Q3 2015.
  • 158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Palisade Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.